Actavis Plc To Buy Forest Labs For $25 Billion; Deal Expected To Be Announced Tuesday

Actavis PLC (NYSE:ACT) is in advanced talks to buy out competing drug maker Forest Labs (NYSE:FRX) in a whopping $25 billion deal expected to be announced early Tuesday, according to media reports. The acquisition of New York-based Forest Labs, which had a market capitalization of $19.3 billion as of Friday, would add a range of generic drugs including Alzheimer's drug,Namenda, and blood-pressure pill, Bystolic, to Actavis' product line-up. On Feb. 14, Actavis had a market value of $33.4 billion...